Company Description
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.
Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.
The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases.
Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies.
Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jul 18, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 76 |
| CEO | Dr. Iain Fraser DPHIL |
Contact Details
Address: 26 Landsdowne Street Cambridge, Massachusetts 02139 United States | |
| Phone | 617-651-8851 |
| Website | fulcrumtx.com |
Stock Details
| Ticker Symbol | FULC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001680581 |
| CUSIP Number | 359616109 |
| ISIN Number | US3596161097 |
| Employer ID | 47-4839948 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Alexander C. Sapir | Chief Executive Officer, President and Director |
| Dr. Bradley E. Bernstein M.D., Ph.D. | Founder |
| Dr. Michael R. Green | Founder |
| Dr. Rudolf Jaenisch M.D., Ph.D. | Founder |
| Dr. Tsun-Huei Lee M.D., Ph.D. | Founder |
| Dr. Danny Reinberg | Founder |
| Alan A. Musso C.M.A., CPA | Chief Financial Officer |
| Gregory Tourangeau | Controller and Principal Accounting Officer |
| Dr. Jeffrey W. Jacobs Ph.D. | Chief Scientific Officer |
| Curtis G. Oltmans J.D. | Senior Vice President, Chief Legal Officer and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 19, 2024 | ARS | Filing |
| Apr 19, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 19, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 8, 2024 | 144 | Filing |
| Feb 27, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Feb 27, 2024 | 10-K | Annual Report |
| Feb 27, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |